|By mouth, IV|
|Metabolism||Mainly unchanged, ~15% N-demethylation|
|Chemical and physical data|
|Molar mass||523.945 g/mol|
|3D model (Jmol)||Interactive image|
Elinogrel (INN, USAN) was an experimental antiplatelet drug acting as a P2Y12 inhibitor. Similarly to ticagrelor and in contrast to clopidogrel, elinogrel was a reversible inhibitor that acted fast and short (for about 12 hours), and it was not a prodrug but pharmacologically active itself. The substance was used in form of its potassium salt, intravenously for acute treatment and orally for long-term treatment. Development was terminated in 2012.
The substance was originally developed by Portola Pharmaceuticals, with Phase II clinical trials conducted around 2008–2011. In February 2009, Novartis bought worldwide rights to develop it further, intending to conduct Phase III studies and commercialise the drug. The development of the drug was terminated in January 2012 by Novartis.
- Siller-Matula, J. M.; Krumphuber, J.; Jilma, B. (2010). "Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases". British Journal of Pharmacology. 159 (3): 502–517. doi:10.1111/j.1476-5381.2009.00555.x. PMC 2828016. PMID 20050853.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 63" (PDF). World Health Organization. pp. 50–1. Retrieved 1 December 2016.
- Gurbel, P.A.; Kereiakes, D.; Tantry, U.S. (2010). "Elinogrel potassium". Drugs Fut. 35 (11): 885.
- Michelson, A. D. (2011). "Advances in Antiplatelet Therapy". Hematology. 2011: 62–69. doi:10.1182/asheducation-2011.1.62. PMID 22160013.
- Insciences: Novartis gains worldwide rights to elinogrel, a Phase II anti-clotting compound with potential to reduce risk of heart attack
- BioPortfolio: Novartis drops elinogrel outright